Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE OF REVIEW: Effective surveillance for and rapid identification of evolved antimalarial resistance ensures that all patients are treated with efficacious drugs. This review summarizes the current status and the challenges to effective surveillance, and suggests approaches for improvement. RECENT FINDINGS: The replacement of older drugs by artemisinin combination therapies (ACTs) as the recommended treatment for malaria has dramatically improved treatment outcomes wherever ACTs have been deployed effectively. Moreover, there has been considerable technical and organizational progress, and support for the health professionals needed to carry out this work is also increasing. As a result, the prospects for more effective surveillance of antimalarial resistance, and other vital health information are improving. However, resistance to the artemisinin component of ACTs is already suspected in Cambodia, and the current methods for tracking this resistance are not yet in place. Identification of efficient markers of ACT efficacy is a crucial challenge. SUMMARY: Technical advances alone are not sufficient. Detection of decreased drug efficacy is only the first step to producing accessible and useful information for decision makers. The translation of increased access to data on health outcomes into usable evidence for rational policy and planning requires a global coordination and communication effort.

Original publication




Journal article


Curr Opin Infect Dis

Publication Date





593 - 600


Antimalarials, Artemisinins, Drug Combinations, Drug Resistance, Humans, Malaria, Population Surveillance, Time Factors, Treatment Outcome